🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Acadia Pharmaceuticals has scored a decisive legal win, with the US Court of Appeals upholding patents for its breakthrough Parkinson’s treatment in a high-stakes battle against MSN Laboratories. Dive deeper into the ruling: ow.ly/hIfc50W76fc

Amanda Ebbutt and Paul England of Taylor Wessing highlight how the UPC, now two years in, is reshaping Europe’s patent landscape—potentially nudging the UK toward reevaluating its stance. Uncover the shifts that may prompt a UK policy rethink: ow.ly/sirj50W76no

15 days to go! Complete the Life Sciences Patent Survey 2025 by 29 June & enter to win a free LSPN Europe 2025 ticket 🎟️ 🧬 Quick, confidential & just 10–15 mins! 💡 Get benchmark insights + early access to findings. Start now: ow.ly/92n750W7IZZ #LifeSciences #IP

Former USPTO director Kathi Vidal has sharply criticised two recent decisions by acting director Coke Morgan Stewart, including the reversal of sanctions against Longhorn Vaccines. Catch up on the growing tensions at the top of the USPTO: ow.ly/OPZ750W8vKv

Synthego has scored a major win at the US Court of Appeals, clearing two Agilent patents on CRISPR guide RNAs as invalid and paving the way for broader therapeutic innovation. Explore what this ruling means for the future of CRISPR therapies:ow.ly/laBv50W8w0H

The Unified Patent Court will roll out a new case management system in two phases starting July 2025, beginning with opt-out and registration features. Stay informed on key UPC system changes and what they mean for users: ow.ly/wqyg50W8w9a

Sheppard Mullin has hired three partners from Perkins Coie—David Fournier, Allison Glasunow, and Kourtney Merrill—to strengthen its IP and life sciences teams in DC and Chicago. Explore how this strategic hire expands Sheppard Mullin’s IP capabilities: ow.ly/Hlp150W8wem

The UPC has permanently blocked Curio Bioscience from selling certain spatial mapping kits in Germany, France, and the Netherlands, marking a major win for 10x Genomics. Find out what this means for biotech IP battles in Europe: ow.ly/S0yF50WblzR

Novo Nordisk has let a key semaglutide patent lapse in Canada, paving the way for generics of its blockbuster drug used in Ozempic and Wegovy. Explore what this means for the future of weight-loss meds in Canada: ow.ly/kiHw50WblBy #Semaglutide #WeightLossMeds #Ozempic

As London Tech Week closes, the UK has unveiled an £8m AI-powered project to revolutionise drug discovery and cut development costs by billions. See how the UK plans to lead the AI pharma revolution: ow.ly/Xl3150WblCB #AIDrugDiscovery #PharmaInnovation

McDermott Will & Emery has added Frédéric Chevallier to its Paris IP team, strengthening its cross-border litigation expertise across Europe. Explore how this move boosts McDermott’s European IP firepower: ow.ly/jIWE50WblEU #IntellectualProperty #LifeSciencesLaw

Regeneron is seeking to disqualify Kirkland & Ellis from representing Novartis in a major patent fight over eye drug Eylea, citing a conflict from the firm’s past work on Regeneron’s IP strategy. Find out what’s at stake in this $6 billion battle: ow.ly/H0LO50Wcn68

Despite efforts to align, the UPC’s Court of Appeal and local divisions are taking different views on how to apply the European Patent Convention—raising questions about consistency. Discover how this split could shape future patent litigation: ow.ly/Im5650Wcng0

Regeneron has filed suit against Amgen, claiming its Eylea biosimilar Pavblu infringes a newly issued patent tied to the blockbuster eye drug’s formulation. See why this latest clash could reshape the biosimilar battlefield: ow.ly/A9nO50Wcnoh #Biologics #PatentLaw

Tokyo’s Isshiki Law Firm has boosted its IP and corporate offering with the hire of Hiromi Furushima, former GC of Novartis Japan and director at Alnylam. Discover how her appointment strengthens Isshiki’s global IP credentials: ow.ly/IamH50WcnsT

Novartis has lost a key European patent for its cancer drug Mekinist, after Teva and Generics UK successfully argued that the formulation lacked inventive step. Discover what this decision means for pharma patents in Europe: ow.ly/3LVN50WfUnG #PharmaNews #CancerResearch

The University of Sheffield has gained ground in its IP fraud battle with AstraZeneca and Kudos Pharmaceuticals, with the UK High Court ordering key disclosures on hypothetical deal structures. Discover how this twist could impact future industry deals: ow.ly/pE1P50WfUs2

Boies Schiller Flexner has bolstered its IP firepower with the hire of Blair Jacobs, Christina Ondrick, and John Holley—three seasoned patent litigators with deep experience. Explore how this move strengthens BSF’s strategic IP expansion: ow.ly/Tlbr50WfUub

Coke Morgan Stewart is shaking up the USPTO’s patent review process with a wave of discretionary denial rulings reinforcing her controversial ‘settled expectations’ standard. Discover why Stewart’s bold new path is dividing the IP world: ow.ly/ULGm50WfUxL

The UPC has rejected Alexion Pharmaceuticals’ bid to reopen its Soliris patent case against Amgen and Samsung Bioepis, calling the rehearing request an “extraordinary remedy.” Explore how this latest setback impacts the future of Soliris in Europe: ow.ly/cqny50WfUza